We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AbCellera (ABCL) to Develop New Antibody Therapies With AbbVie
Read MoreHide Full Article
AbCellera Biologics Inc. (ABCL - Free Report) announced that it entered a multi-target strategic collaboration with pharma giant AbbVie (ABBV - Free Report) to develop new antibody therapies.
Per the agreement, AbCellera is eligible to receive research payments, as well as certain milestone payments and royalties on net sales, if a product is commercialized from the above collaboration. AbbVie will have the right to develop/commercialize therapeutic antibodies developed under the partnership.
Per the company, the latest deal is looking to leverage ABCL’s antibody drug discovery engine to deliver optimized pipeline candidates for up to five targets that are selected by ABBV across multiple indications.
Shares of AbCellera were up 2.7% on Thursday, following the announcement of the news. The stock has declined 27.3% so far this year compared with the industry’s fall of 17.3%.
Image Source: Zacks Investment Research
Apart from the deal with AbbVie, ABCL’s technology stack led to collaborations with several big and small healthcare companies for the discovery of antibodies across multiple indications.
Earlier this month, AbCellera inked a strategic alliance with Connecticut-based Rallybio Corporation (RLYB - Free Report) to discover, develop and commercialize novel antibody-based therapeutics for rare diseases.
This multi-year partnership is looking to combine AbCellera’s antibody discovery engine with Rallybio’s expertise in rare diseases to identify optimal candidates while delivering therapies to patients.
AbCellera and RLYB will develop up to five rare disease therapeutic targets.
AbCellera’s top line currently comprises royalties, research fees from partnerships, and revenues from milestone payments and licensing revenues. Such partnership deals remain key factors for the company’s growth in the long run.
Loss per share estimates for ASLAN Pharmaceuticals have narrowed to 6.1% for 2022 and 5.7% for 2023 in the past 60 days.
Earnings of ASLAN Pharmaceuticals surpassed estimates in two of the trailing four quarters and missed on the remaining two occasions. ASLN witnessed an earnings surprise of 1.64% on average.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
AbCellera (ABCL) to Develop New Antibody Therapies With AbbVie
AbCellera Biologics Inc. (ABCL - Free Report) announced that it entered a multi-target strategic collaboration with pharma giant AbbVie (ABBV - Free Report) to develop new antibody therapies.
Per the agreement, AbCellera is eligible to receive research payments, as well as certain milestone payments and royalties on net sales, if a product is commercialized from the above collaboration. AbbVie will have the right to develop/commercialize therapeutic antibodies developed under the partnership.
Per the company, the latest deal is looking to leverage ABCL’s antibody drug discovery engine to deliver optimized pipeline candidates for up to five targets that are selected by ABBV across multiple indications.
Shares of AbCellera were up 2.7% on Thursday, following the announcement of the news. The stock has declined 27.3% so far this year compared with the industry’s fall of 17.3%.
Image Source: Zacks Investment Research
Apart from the deal with AbbVie, ABCL’s technology stack led to collaborations with several big and small healthcare companies for the discovery of antibodies across multiple indications.
Earlier this month, AbCellera inked a strategic alliance with Connecticut-based Rallybio Corporation (RLYB - Free Report) to discover, develop and commercialize novel antibody-based therapeutics for rare diseases.
This multi-year partnership is looking to combine AbCellera’s antibody discovery engine with Rallybio’s expertise in rare diseases to identify optimal candidates while delivering therapies to patients.
AbCellera and RLYB will develop up to five rare disease therapeutic targets.
AbCellera’s top line currently comprises royalties, research fees from partnerships, and revenues from milestone payments and licensing revenues. Such partnership deals remain key factors for the company’s growth in the long run.
Zacks Rank & Stocks to Consider
AbCellera currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the biotech sector is ASLAN Pharmaceuticals Limited (ASLN - Free Report) , carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Loss per share estimates for ASLAN Pharmaceuticals have narrowed to 6.1% for 2022 and 5.7% for 2023 in the past 60 days.
Earnings of ASLAN Pharmaceuticals surpassed estimates in two of the trailing four quarters and missed on the remaining two occasions. ASLN witnessed an earnings surprise of 1.64% on average.